ResearcherThe University of Texas Southwestern Medical CenterActive in the last 2 years
Emile Farah
Matched on ORCID iD 0000-0003-4176-5504; OpenAlex author ID A5092668169. Sources: OpenAlex.
Their work
- Papers
- 3
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 19
2024: 1 paper · 2025: 1 paper · 2026: 1 paper
Papers 3
- Pretreatment CA19-9 Predicts Survival in Pancreatic Cancer With Optimal Response to Neoadjuvant Therapy. Co-author DOI 10.1002/jso.70179↗
- Multimodal Therapy May be Key to Improving Survival for Octogenarians Undergoing Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma: An American Mult… Co-author DOI 10.1245/s10434-025-16916-7↗
- Minimally invasive pancreaticoduodenectomy: A favorable approach for frail patients with pancreatic cancer. Co-author DOI 10.1016/j.surg.2023.12.022↗
Closest collaborators
The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Patricio Marcelo Polanco · 3 shared papers, 2024–2026 · strength 0.63
- Paper Pretreatment CA19-9 Predicts Survival in Pancreatic Cancer With Optimal Response to Neoadjuvant Therapy. DOI 10.1002/jso.70179↗
- Paper Minimally invasive pancreaticoduodenectomy: A favorable approach for frail patients with pancreatic cancer. DOI 10.1016/j.surg.2023.12.022↗
- Paper Multimodal Therapy May be Key to Improving Survival for Octogenarians Undergoing Pancreaticoduodenectomy for Pancreatic… DOI 10.1245/s10434-025-16916-7↗
- Herbert J. Zeh · 3 shared papers, 2024–2026 · strength 0.63
- Paper Pretreatment CA19-9 Predicts Survival in Pancreatic Cancer With Optimal Response to Neoadjuvant Therapy. DOI 10.1002/jso.70179↗
- Paper Minimally invasive pancreaticoduodenectomy: A favorable approach for frail patients with pancreatic cancer. DOI 10.1016/j.surg.2023.12.022↗
- Paper Multimodal Therapy May be Key to Improving Survival for Octogenarians Undergoing Pancreaticoduodenectomy for Pancreatic… DOI 10.1245/s10434-025-16916-7↗
- Melissa Ellen Hogg · 2 shared papers, 2025–2026 · strength 0.42
- Sarah B. Hays · 2 shared papers, 2025–2026 · strength 0.42
- Asmita Chopra · 2 shared papers, 2025–2026 · strength 0.42
- Amer H. Zureikat · 2 shared papers, 2025–2026 · strength 0.42
- Mark S. Talamonti · 2 shared papers, 2025–2026 · strength 0.42
- Brian A. Boone · 2 shared papers, 2025–2026 · strength 0.42
- Alessandro Paniccia · 2 shared papers, 2025–2026 · strength 0.42
- Anthony Gebran · 1 shared paper, 2026 · strength 0.23
- Sebastiaan Ceuppens · 1 shared paper, 2026 · strength 0.23
- Amr I. Al Abbas · 1 shared paper, 2024 · strength 0.21
- John C. Mansour · 1 shared paper, 2024 · strength 0.21
- Adam Charles Yopp · 1 shared paper, 2024 · strength 0.21
- Matthew R. Porembka · 1 shared paper, 2024 · strength 0.21
- Sam C. Wang · 1 shared paper, 2024 · strength 0.21
- Caroline J. Rieser · 1 shared paper, 2025 · strength 0.19
- Amudhan Kannan · 1 shared paper, 2025 · strength 0.19
- Imad Radi · 1 shared paper, 2025 · strength 0.19
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.